A prospective phase II trial of vinblastine and methotrexate in multivessel intraluminal pulmonary vein stenosis in infants and children

• Published in: Congenital heart disease Vol. 6; no. 6; p. 608
• Main Authors: Rehman, Maliha, Jenkins, Kathy J, Juraszek, Amy L, Connor, Jean A, Gauvreau, Kimberlee, Muneeb, Muhammad, Sena, Laureen M, Colan, Steven D, Saia, Terry, Kieran, Mark W
• Format: Journal Article
• Language: English
• Published: United States 01.11.2011
• Subjects: Cell Proliferation - drug effects; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; Methotrexate - administration & dosage; Methotrexate - adverse effects; Methotrexate - therapeutic use; Myofibroblasts - drug effects; Myofibroblasts - pathology; Prospective Studies; Pulmonary Veins - drug effects; Pulmonary Veins - pathology; Pulmonary Veno-Occlusive Disease - diagnostic imaging; Pulmonary Veno-Occlusive Disease - drug therapy; Pulmonary Veno-Occlusive Disease - mortality; Pulmonary Veno-Occlusive Disease - pathology; Survival Rate; Texas; Time Factors; Treatment Outcome; Ultrasonography; Vinblastine - administration & dosage; Vinblastine - adverse effects; Vinblastine - therapeutic use

To determine the safety and efficacy of the chemotherapeutic agents vinblastine and methotrexate in the treatment of children with progressive multivessel intraluminal pulmonary vein stenosis (PVS). Children received weekly vinblastine and methotrexate for a period of 1 year. Outcomes (for patients...